SCHEMBL2663071

SCHEMBL2663071

CC(C)c1cc(C(C)C)c(C(C)O)c(-c2ccc(F)cc2)c1CSc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.55

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
GCGR P47871 8/20 0.55
CASR P41180 1/20 0.33
PPARD Q03181 2/20 0.33
PPARA Q07869 2/20 0.33
ALOX5 P09917 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.32
EPHX1 P07099 1/20 0.32
HSD11B1 P28845 1/20 0.32
SCN10A Q9Y5Y9 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2647443 0.89 GCGR (0.67) GCGR
SCHEMBL2663067 0.89 GCGR (0.58) GCGR
SCHEMBL2663070 0.87 GCGR (0.58) GCGRPPARDPPARA
SCHEMBL2647652 0.85 GCGR (0.62) GCGR
SCHEMBL2649721 0.85 GCGR (0.62) GCGR
SCHEMBL2665676 0.85 GCGR (0.62) GCGRALOX5
SCHEMBL2648686 0.84 GCGR (0.61) GCGR
SCHEMBL2647610 0.84 GCGR (0.60) GCGR
SCHEMBL2648884 0.79 GCGR (0.52) GCGR
SCHEMBL2648169 0.77 GCGR (0.54) GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6218431-B1 GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES BAYER CORPORATION 2001-04-17 US disclosed
US-6218431-B1 GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES BAYER CORPORATION 2001-04-17 US disclosed
WO-1998004528-A2 SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS BAYER CORPORATION (US) 1998-02-05 WO disclosed